Therapeutic management of metabolic dysfunction associated steatotic liver disease

United European Gastroenterology Journal, Journal Year: 2024, Volume and Issue: 12(2), P. 177 - 186

Published: Jan. 9, 2024

Abstract The incidence and prevalence of non‐alcoholic fatty liver disease (NAFLD) have been steadily increasing worldwide, with a huge societal economic burden. Recently, NAFLD steatohepatitis renamed redefined as metabolic dysfunction associated steatotic (MASLD) (Metabolic Dysfunction Associated Steatohepatitis (MASH)), which result from an imbalance between inflammatory stress (mainly consequence adipose tissue insulin resistance) the defence repair mechanisms liver. Once MASLD progresses to end‐stage disease, treatment efficacy becomes limited may require transplantation. Early detection intervention are crucial. Lifestyle modification is consequently cornerstone its management. Timely consideration bariatric surgeries should be given patients meeting specific criteria. A multidisciplinary approach warranted, starting concept that MASLD/MASH at centre cardiovascular‐liver‐metabolic syndrome. In some cases, pharmacological can complement lifestyle modification. Several drugs used treat cardiometabolic co‐morbidities potential in slowing Down progression, demonstrated on histological endpoints likely translate into long‐term clinical benefits. Optimising use these within their licenced indications thus paramount for MASLD. MASH‐specific horizon enrich our therapeutic armamentarium near future, particularly non‐cirrhotic stages disease. Much work still needs done understand features MASH cirrhosis develop efficacious treatments this stage.

Language: Английский

---

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases

Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12

Published: July 16, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty (NAFLD), is the most common disorder worldwide, with an estimated global prevalence of more than 31%. steatohepatitis (MASH), formerly (NASH), a progressive form MASLD characterized by hepatic steatosis, inflammation, and fibrosis. This review aims to provide comprehensive analysis extrahepatic manifestations MASH, focusing on chronic diseases related cardiovascular, muscular, renal systems. A systematic published studies literature was conducted summarize findings systemic impacts MASH. The focused association MASH metabolic comorbidities, cardiovascular mortality, sarcopenia, kidney disease. Mechanistic insights into concept lipotoxic inflammatory "spill over" from MASH-affected were also explored. are highly associated (50%-80%) other comorbidities such impaired insulin response, type 2 diabetes, dyslipidemia, hypertriglyceridemia, hypertension. Furthermore, 90% obese patients diabetes have Data suggest that in middle-aged individuals (especially those aged 45-54), independent risk factor for plays crucial role mediating pathological effects observed. Understanding multifaceted impact heart, muscle, early detection stratification. knowledge timely implementing management strategies addressing multi-organ involvement pathogenesis.

Language: Английский

---

High-Intensity Interval Training Reduces Liver Enzyme Levels and Improves MASLD-Related Biomarkers in Overweight/Obese Girls

Nutrients, Journal Year: 2025, Volume and Issue: 17(1), P. 164 - 164

Published: Jan. 1, 2025

Background/Objectives: Despite the abundant body of evidence linking high-intensity interval training (HIIT) to cardiometabolic markers, little is known about how HIIT affects liver enzymes, particularly in obese adolescents. This study aimed investigate effects on metabolic dysfunction-associated steatotic disease (MASLD)-related biomarkers overweight/obese adolescent girls. Methods: Thirty-three girls (age, 17.0 ± 1.15 yr.; mass index, 33.3 4.77 kg/m2) were randomly assigned (n = 17) or control 16) groups. The group participated a nine-week program (three times weekly) without caloric restriction. Maximal aerobic speed, composition indexes, blood pressure, MASLD-related [liver enzymes (alanine aminotransferase (ALT) and aspartate (AST)), plasma lipids, uric acid, platelet count, homeostasis model assessment index for insulin-resistance (HOMA-IR)] examined at baseline after intervention. Results: Significant “time × group” interactions found systolic maximal ALT AST, glucose, HOMA-IR. resulted an increase speed (p 0.035) decrease lipids < 0.01), pressure 0.011), 0.013), AST 0.012), HOMA-IR but no significant changes acid count. None these markers changed group. Conclusions: improvement biomarkers. could be effective exercise therapy prevent reverse MASLD adolescents with obesity.

Language: Английский

---

Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy

Cells, Journal Year: 2025, Volume and Issue: 14(3), P. 221 - 221

Published: Feb. 4, 2025

Cigarette smoke (CS), an intricate blend comprising over 4000 compounds, induces abnormal cellular reactions that harm multiple tissues. Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic (CLD), encompassing non-alcoholic (NAFL), steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). Recently, the term NAFLD has been changed to metabolic dysfunction-associated steatotic (MASLD), NASH renamed (MASH). A multitude of experiments have confirmed association between CS incidence progression MASLD. However, specific signaling pathways involved need be updated with new scientific discoveries. exposure can disrupt lipid metabolism, induce inflammation apoptosis, stimulate fibrosis through promote Currently, there no officially approved efficacious pharmaceutical intervention in clinical practice. Therefore, lifestyle modifications emerged as primary therapeutic approach for managing Smoking cessation application series natural ingredients shown ameliorate pathological changes induced by CS, potentially serving effective decelerating MASLD development. This article aims elucidate which smoking promotes MASLD, while summarizing reversal factors identified recent studies, thereby offering novel insights future research on treatment

Language: Английский

---

Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)

Journal of Clinical and Translational Hepatology, Journal Year: 2024, Volume and Issue: 000(000), P. 000 - 000

Published: Nov. 4, 2024

With the rising epidemic of obesity, metabolic syndrome, and type 2 diabetes mellitus in China, dysfunction-associated non-alcoholic fatty liver disease has become most prevalent chronic disease. This condition frequently occurs Chinese patients with alcoholic hepatitis B. To address impending public health crisis its underlying issues, Society Hepatology Medical Association convened a panel clinical experts to revise update "Guideline prevention treatment (2018, China)". The new edition, titled for (Version 2024)", offers comprehensive recommendations on key including screening monitoring, diagnosis evaluation, treatment, follow-up steatotic Metabolic is now preferred English term used interchangeably Additionally, guideline emphasizes importance multidisciplinary collaboration among hepatologists other specialists manage cardiometabolic disorders effectively.

Language: Английский

---

The correlation between heavy metal ions in blood and metabolic dysfunction-associated steatotic liver disease from 1999 to 2018 based on NHANES data

Frontiers in Public Health, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 7, 2025

Metabolic-associated steatohepatitis and liver fibrosis (MASLD) is a growing public health concern, with environmental factors potentially playing role in its development. This study aimed to investigate the associations between serum cadmium mercury levels risk of MASLD nationally representative sample from United States. Data National Health Nutrition Examination Survey 1999 2018 were analyzed. Serum concentrations measured, was defined based on established criteria. Logistic regression models used assess metal MASLD, adjustments for potential confounders. Stratified analyses restricted cubic spline curves employed examine subgroup differences nonlinear relationships. The revealed significant inverse likelihood MASLD. Individuals highest quartiles had lower odds compared those lowest (Model 3: Cadmium Q4 vs. Q1, Mercury Q1). showed stronger older adults, males, never smokers cadmium, females individuals without diabetes mercury. Nonlinear dose-response indicated critical thresholds beyond which dynamics changed. Higher associated notable variations across subgroups. These findings challenge conventional understanding these heavy metals as universally harmful highlight need further research unravel complex interplay exposures pathophysiology.

Language: Английский

---

Characterization of liver, adipose, and fecal microbiome in obese patients with MASLD: links with disease severity and metabolic dysfunction parameters

Microbiome, Journal Year: 2025, Volume and Issue: 13(1)

Published: Jan. 14, 2025

Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a range of histological findings from the generally benign simple steatosis to steatohepatitis (MASH) which can progress fibrosis and cirrhosis. Several factors, including microbiome, may contribute progression. Results Here, we demonstrate links between presence abundance specific bacteria in adipose tissues, inflammatory genes, immune cell responses, severity. Overall, MASLD patients, observed generalized obesity-induced translocation gut hepatic tissues. We identified microbial patterns unique more severely diseased Specifically, Enterococcus , Granulicatella Morganellaceae is positively correlated with counts gene expression levels, both genera are significantly enriched MASH patients. Brevibacterium tissues patients fibrosis. Conclusion Together, these results provide further insight into factors that be driving

Language: Английский

---

MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists

Diabetes Research and Clinical Practice, Journal Year: 2024, Volume and Issue: 212, P. 111688 - 111688

Published: May 1, 2024

Language: Английский

---

Global research trends on gut microbiota and metabolic dysfunction-associated steatohepatitis: Insights from bibliometric and scientometric analysis

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: July 11, 2024

Background Metabolic dysfunction-associated steatohepatitis (MASH) is an inflammatory subtype of metabolic steatotic liver disease (MASLD) has recently been proposed as a replacement term for NAFLD, common, multifactorial and poorly understood whose incidence increasing worldwide. In recent years, there scientific interest in exploring the relationship between gut microbiota MASH. To learn more about MASH, this study aims to provide comprehensive analysis knowledge structure research hotspots from bibliometric perspective. Methods We searched Web Science Core Collection articles reviews that covered connections MASH over last decade. The Online Analysis Platforms, VOSviewer, CiteSpace, R tool “bibliometrix” were used analyzed existing publications trends hotspots. Results A total 4,069 documents related interaction retrieved 2014 2023. number annual increased significantly decade, particularly United States China. University California-San Diego was most productive institution, while researcher Rohit Loomba published papers field. Younossi ZM ranked first co-cited author largest contributor highly cited Gastroenterology hepatology common specialty category. journal decade Hepatology. Keyword Bursts highlighted importance studying association well factors such syndrome, insulin resistance, endotoxemia overgrowth bacteria. clusters with co-citation illustrate important topics including intestinal permeability, sensitivity immunology. keywords include obesity, dysbiosis, inflammation oxidative stress, which are current Conclusion Our highlights key aspects field emphasizes multiorgan crosstalk MASLD/MASH pathogenesis. particular, central role gut-liver axis significant influence dysbiosis on progression highlighted. Furthermore, our results highlight transformative potential microbiota-specific therapies cover way innovative healthcare pharmaceutical strategies.

Language: Английский

---

Insulin resistance as a mediator in the association between nickel exposure and metabolic dysfunction-associated steatotic liver disease

Diabetology & Metabolic Syndrome, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 7, 2025

The myriad implications of heavy metal pollution on human health have garnered substantial attention within the academic domain. Nevertheless, a notable research gap persists, as there is currently insufficient direct investigation elucidating intricate interplay between nickel exposure and risk metabolic dysfunction-associated steatotic liver disease (MASLD). data utilized in this study was sourced from National Health Nutrition Examination Survey 2017–2020. Hepatic steatosis evaluated utilizing controlled attenuation parameters (CAP), level reflected by urinary concentration. To analyze association MASLD, three multiple logistic regression models with weights were developed. Furthermore, mediation analysis performed to examine insulin resistance's potential mediating role. There total 1,187 participants study, which 548 (46.17%) had MASLD. MASLD individuals significantly higher concentration than non-MASLD (P = 0.008). After accounting for demographic factors, biochemical indicators, conditions, odds ratio (OR) 95% confidence interval (CI) 2.10 (1.09–4.05) per onefold increase 2.61 (1.22–5.55) highest tertile versus lowest tertile. Insulin resistance found mediate approximately 73.69% 0.004). Nickel independently associated prevalence Excessive may promote occurrence enhancing resistance.

Language: Английский

---